Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Fish and Richardson
Express Scripts
Teva
UBS

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 5,677,278

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,677,278
Title: Truncated keratinocyte growth factor (KGF) having increased biological activity
Abstract:The present invention relates to a keratinocyte growth factor fragment, KGF.sub.des1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF.sub.163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant keratinocyte growth factor, rKGF, but lacks a sequence comprising the first 23 amino acid residues, C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R- (SEQ ID NO: 2) of the KGF.sub.163 N-terminus. The present invention also relates to a DNA molecule encoding KGF.sub.des1-23, an expression vector and a transformed host containing the DNA molecule, and a method of producing KGF.sub.des1-23 by culturing the transformed host. The present invention further relates to a conjugate of KGF.sub.des1-23 and a toxin molecule, and the use thereof for treatment of hyperproliferative disease of the epidermis. Moreover, the present invention relates to a therapeutic composition containing KGF.sub.des1-23 and a pharmaceutically acceptable carrier and the use thereof for wound healing purposes.
Inventor(s): Gospodarowicz; Denis J. (Lafayette, CA), Masiarz; Frank R. (San Francisco, CA)
Assignee: Chiron Corporation (Emeryville, CA)
Application Number:08/410,941
Patent Claims:see list of patent claims

Details for Patent 5,677,278

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Try a Free Trial Chiron Corporation (Emeryville, CA) 2036-04-30 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Mallinckrodt
Cipla
Daiichi Sankyo
Boehringer Ingelheim
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.